JP2011529886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529886A5 JP2011529886A5 JP2011521135A JP2011521135A JP2011529886A5 JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5 JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- dimethylpyridin
- difluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- -1 1-cyclopropyl-2-methoxyethyl Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- LGFBVFFBJBSDGC-UHFFFAOYSA-N 1,2-dihydropyrazine-5-carbonitrile Chemical compound N#CC1=CNCC=N1 LGFBVFFBJBSDGC-UHFFFAOYSA-N 0.000 claims 1
- PJMUNXORSUNUCV-OAHLLOKOSA-N 4-[(1s)-1-cyclopropyl-2-methoxyethyl]-6-[[6-(difluoromethoxy)-2,5-dimethylpyridin-3-yl]amino]-5-oxopyrazine-2-carbonitrile Chemical compound C1([C@@H](COC)N2C(C(NC=3C(=NC(OC(F)F)=C(C)C=3)C)=NC(=C2)C#N)=O)CC1 PJMUNXORSUNUCV-OAHLLOKOSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8523008P | 2008-07-31 | 2008-07-31 | |
| US61/085,230 | 2008-07-31 | ||
| PCT/US2009/041793 WO2010014280A1 (en) | 2008-07-31 | 2009-04-27 | Pyrazinone modulator of corticotropin-releasing factor receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529886A JP2011529886A (ja) | 2011-12-15 |
| JP2011529886A5 true JP2011529886A5 (enExample) | 2012-05-24 |
| JP5396474B2 JP5396474B2 (ja) | 2014-01-22 |
Family
ID=40651774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521135A Expired - Fee Related JP5396474B2 (ja) | 2008-07-31 | 2009-04-27 | 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7932256B2 (enExample) |
| EP (1) | EP2303867B1 (enExample) |
| JP (1) | JP5396474B2 (enExample) |
| KR (1) | KR20110040870A (enExample) |
| CN (1) | CN102171205B (enExample) |
| AR (1) | AR072639A1 (enExample) |
| AU (1) | AU2009277057A1 (enExample) |
| MX (1) | MX2011000754A (enExample) |
| TW (1) | TW201008926A (enExample) |
| WO (1) | WO2010014280A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| RU2015119411A (ru) | 2012-11-15 | 2017-01-10 | Рош Инновейшен Сентер Копенгаген А/С | Конъюгаты антисмысловых соединений, направленные на аполипопротеин в |
| WO2014118267A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Lna oligonucleotide carbohydrate conjugates |
| CN106102740A (zh) | 2014-01-21 | 2016-11-09 | 纽罗克里生物科学有限公司 | 治疗先天性肾上腺增生的crf1受体拮抗剂 |
| EP3984523B1 (en) | 2018-12-07 | 2025-09-03 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| WO2021062246A1 (en) | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| IT201900021216A1 (it) | 2019-11-14 | 2021-05-14 | Isagro Spa | Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine |
| CN112552184B (zh) * | 2020-12-18 | 2022-05-10 | 诚达药业股份有限公司 | 一种含环丙基手性胺盐酸盐的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE213495T1 (de) | 1996-09-16 | 2002-03-15 | Du Pont Pharm Co | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper |
| NZ520484A (en) * | 2000-02-16 | 2005-03-24 | Neurogen Corp | Substituted arylpyrazines that are modulators of CRF (corticotropin releasing factor) receptor and methods of treatment using them |
| HRP20031096A2 (en) * | 2001-06-12 | 2005-08-31 | Neurogen Corporation | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| AU2003278542A1 (en) | 2002-11-21 | 2004-06-15 | Pharmacia & Upjohn Company Llc | Pyrazine compounds as crf modulators |
-
2009
- 2009-04-24 US US12/429,810 patent/US7932256B2/en active Active
- 2009-04-27 CN CN2009801386016A patent/CN102171205B/zh not_active Expired - Fee Related
- 2009-04-27 KR KR1020117002253A patent/KR20110040870A/ko not_active Withdrawn
- 2009-04-27 AU AU2009277057A patent/AU2009277057A1/en not_active Abandoned
- 2009-04-27 JP JP2011521135A patent/JP5396474B2/ja not_active Expired - Fee Related
- 2009-04-27 EP EP09789614.6A patent/EP2303867B1/en not_active Not-in-force
- 2009-04-27 MX MX2011000754A patent/MX2011000754A/es active IP Right Grant
- 2009-04-27 WO PCT/US2009/041793 patent/WO2010014280A1/en not_active Ceased
- 2009-07-22 TW TW098124751A patent/TW201008926A/zh unknown
- 2009-07-30 AR ARP090102928A patent/AR072639A1/es not_active Application Discontinuation
-
2011
- 2011-03-21 US US13/052,458 patent/US8372847B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529886A5 (enExample) | ||
| JP2015502951A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2016503785A5 (enExample) | ||
| EP2312945A4 (en) | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| PE20081377A1 (es) | Compuestos de tiazol pirazolopirimidina | |
| JP2008513516A5 (enExample) | ||
| WO2008062905A3 (en) | Heteromonocyclic compound and use thereof | |
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| EP2312946A4 (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| JP2017524005A5 (enExample) | ||
| JP2009514835A5 (enExample) | ||
| ZA201006868B (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
| EP2385951A4 (en) | PHOSPHORAMIDATE DERIVATIVES FROM GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| SI3074386T1 (en) | New aminopyrimidine derivatives | |
| EP2173344A4 (en) | TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEUROPSYCHIATRIC ILLNESSES BY OCULAR ADMINISTRATION | |
| JP2004517852A5 (enExample) | ||
| WO2008006547A3 (en) | Pyrrolopyrimidines for pharmaceutical compositions | |
| WO2007070598A8 (en) | Nucleotide and oligonucleotide prodrugs | |
| WO2008130678A3 (en) | Rosuvastatin intermediates and process for the preparation of rosuvastatin | |
| JP2009510064A5 (enExample) | ||
| HK1206597A1 (en) | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof | |
| JP2019517996A5 (enExample) | ||
| WO2008098985A3 (en) | Pharmaceutical composition for the treatment of il-8 mediated diseases |